Changeflow GovPing Pharma & Drug Safety Improved Combination of Protease and Protease I...
Routine Notice Added Final

Improved Combination of Protease and Protease Inhibitor with Secondary Enzyme

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent EP4217368A1, granted to BASF SE, covering an improved combination of protease and protease inhibitor with secondary enzyme. The invention relates to protease-protease inhibitor compositions for industrial applications, classified under C07K, C11D, and C12N. The patent is designated across 31 European states including DE, FR, GB, IT, ES, and NL.

What changed

EPO granted patent EP4217368A1 to BASF SE for an invention relating to an improved combination of protease and protease inhibitor with secondary enzyme. The patent covers compositions and methods for industrial applications using protease-protease inhibitor combinations, with IPC classifications spanning pharmaceutical chemistry (C07K), cleaning compositions (C11D), and enzyme technology (C12N).

Pharmaceutical and chemical companies developing enzyme-based products should monitor this patent portfolio. The designated states cover major European markets, making this relevant for any entity operating in the European enzyme or cleaning product space. While patent grants do not impose compliance obligations, companies may wish to evaluate whether their R&D activities could fall within the scope of these claims.

What to do next

  1. Monitor for updates if developing protease-based formulations
  2. Review patent claims for potential licensing considerations

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

IMPROVED COMBINATION OF PROTEASE AND PROTEASE INHIBITOR WITH SECONDARY ENZYME

Publication EP4217368A1 Kind: A1 Apr 01, 2026

Applicants

BASF SE

Inventors

JENEWEIN, Stefan, BOENEMANN, Gabriele

IPC Classifications

C07K 5/083 20060101AFI20220402BHEP C11D 3/20 20060101ALI20220402BHEP C12N 9/14 20060101ALI20220402BHEP C11D 3/32 20060101ALI20220402BHEP C11D 3/386 20060101ALI20220402BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4217368A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing IP portfolio management
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Chemical Manufacturing

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.